secwatch.observer — SEC 8-K summary
======================================

Issuer:     OmniAb, Inc. (OABI)
CIK:        0001846253
Form:       8-K
Filed at:   2024-11-12T23:59:59+00:00
Accession:  0001846253-24-000086
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

OmniAb Q3 2024 revenue $4.2M (down 24% YoY), net loss $16.4M; partner pipeline grows
--------------------------------------------------------------------------------

- Q3 2024 revenue $4.2M (down 24% YoY); net loss $16.4M ($0.16/sh) vs $15.7M ($0.16/sh) in Q3 2023.
- Cash $59.4M at Sept 30; sold 2.0M shares via ATM for $8.5M in Q3, plus $2.9M post-quarter.
- FY 2024 total opex expected slightly below 2023; FY 2024 cash balance guided at $50-60M.
- Entered three new platform licenses in Q3 (92Bio, MSKCC, Queen Mary London) plus Incyte after quarter.
- Partner events: Immunovant IMVT-1402 IND cleared in RA; Genmab to start Ph3 for acasunlimab; CStone sugemalimab UK approval.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1846253/000184625324000086/0001846253-24-000086-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1846253/000184625324000086/oabi-20241112.htm
  HTML page:      https://secwatch.observer/filing/0001846253-24-000086

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer